Company intelligence / Profile preview

Forchronic

Ownership: Private
Development stage: Commercial

Overview

Forchronic is a biotechnology company leveraging academic knowledge from the Autonomous University of Madrid. It has launched at least one commercial nutraceutical product, Immunelipchronic, aimed at supporting immune health in chronic conditions. There is no public information about clinical trial results for pharmaceutical candidates.

Therapeutic areas: OtherImmunology
Modalities: Small moleculeNutraceutical product
Industry: Food & Nutrition

Drug pipeline

2 assets

CBD Plus

Commercial

Indications: Chronic diseases

1 more asset in the full pipeline.

Request access →

Partnerships

Academic partnership with Autonomous University of Madrid

Beyond the preview

Go deeper on Forchronic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forchronic.

Explore the full profile